Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 9, 2013, Pages 1384-1393

  Carrasquillo, Jorge A ^a,b   O'Donoghue, Joseph A ^a   Pandit Taskar, Neeta ^a,b   Humm, John L ^a   Rathkopf, Dana E ^a,b   Slovin, Susan F ^a,b   Williamson, Matthew J ^a   Lacuna, Kristine ^a   Aksnes, Anne Kirsti ^c   Larson, Steven M ^a,b   Scher, Howard I ^a,b   Morris, Michael J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Algeta AS   (Norway)

Author keywords

223Ra; Alpharadin; Bone metastases; Prostate cancer; Radionuclide therapy; Radium

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; BODY DISTRIBUTION; CALCIUM BLOOD LEVEL; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DIARRHEA; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; ECHO PLANAR IMAGING; FATIGUE; FECES; HUMAN; LEUKOPENIA; MALE; MEASUREMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA VOLUME; PROGENY; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY EXCRETION; VASCULARIZATION; WHOLE BODY COUNTING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENDPOINT DETERMINATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; TISSUE DISTRIBUTION;

EID: 84881630281     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2427-6     Document Type: Article

References (39)

1. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001;20:333-49. doi: 10.1023/a:1015599831232.
2. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84. doi: 10.1093/annonc/mdi122.
3. Agarawal JP, Swangsilpa T, van der Linden Y, Rades D, Jeremic B, Hoskin PJ. The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol) 2006;18:747-60. doi: 10.1016/j.clon.2006.09.007.
4. Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer 2010;8:29-36. doi: 10.3816/CGC.2010.n.005.
5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82. doi: 10.1093/jnci/djh141.
6. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993;34:1839-44.
7. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
8. Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012;48:678-86. doi: 10.1016/j.ejca.2011.12.023.
9. Parker C, Heinrich D, Helle SI, O'Sullivan JM, Fossä S, Chodacki A, et al. Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: a phase III randomized trial (ALSYMPCA). Eur Urol Suppl 2012;11:E130-U523.
10. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451-9.
11. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-94. doi: 10.1016/s1470-2045(07)70147-x.
12. Larsen RH, Saxtorph H, Skydsgaard M, Borrebaek J, Jonasdottir TJ, Bruland OS, et al. Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology. In Vivo 2006;20:325-31.
13. Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003;44:252-9.
14. Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle- emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120-5.
15. Henriksen G, Hoff P, Alstad J, Larsen RH. 223Ra for endoradiotherapeutic applications prepared from an immobilized 227Ac/227Th source. Radiochim Acta 2001;89:661-6.
16. Skarsgard LD. Radiobiology with heavy charged particles: a historical review. Phys Med 1998;14:1-19.
17. Neuman WF, Hursh JB, Boyd J, Hodge HC. On the mechanism of skeletal fixation of radium. Ann N Y Acad Sci 1955;62:125-36.
18. Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, et al. A bone marrow toxicity model for 223Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol 2012;57:3207-22. doi: 10.1088/0031-9155/57/10/3207.
19. Seil HA, Viol CH, Gordon MA. The elimination of soluble radium salts taken intravenously and per os. N Y Med J 1915;18:896-8.
20. Harrison GE, Carr TEF, Sutton A. Distribution of radioactive calcium, strontium, barium and radium following intravenous injection into a healthy man. Int J Radiat Biol Relat Stud Phys Chem Med 1967;13:235-47.
21. Hoecker FE, Roofe PG. Studies of radium in human bone. Radiology 1951;56:89-98.
22. Holtzman RB, Lucas HF, Stehney AF. Excretion rates and blood levels of 226Ra and 210Pb in long-term radium-injected patients. Health Phys 1973;25:335.
23. Mays CW, Atherton DR, Christensen WR, Pitchfor G, Lloyd RD. Radium metabolism in a man. Radiat Res 1963;19:210.
24. Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H. Malignancies in patients treated with high doses of radium-224. Radiat Res 1999;152:S3-7.
25. Norris WP, Speckman TW, Gustafson PF. Studies of the metabolism of radium in humans. Radiat Res 1954;1:555.
26. Shelley MD, Mason MD. Radium-223 for men with hormone-refractory prostate cancer and bone metastases. Lancet Oncol 2007;8:564-5.
27. Tiepolt C, Grüning T, Franke WG. Renaissance of 224Ra for the treatment of ankylosing spondylitis: clinical experiences. Nucl Med Commun 2002;23:61-6.
28. Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun 2012;33:726-32. doi: 10.1097/MNM.0b013e328353bb6e.
29. Bergeron DE, Zimmerman BE, Cessna JT. Development of secondary standards for 223Ra. Appl Radiat Isot 2010;68:1367-70. doi: 10.1016/j.apradiso.2009.11. 005.
30. Retzlaff JA, Tauxe WN, Kiely JM, Stroebel CF. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood 1969;33:649-61.
31. NCI CTEP. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctepcancergov/protocolDevelopment/electronic-applications/docs/ ctcaev3pdf. 2006 ed: National Cancer Institute, NIH; 2006.
32. Harrison GE, Carr TEF, Sutton A, Rundo J. Plasma concentration and excretion of calcium-47, strontium-85, barium-133 and radium-223 following successive intravenous doses to a healthy man. Nature 1966;209:526-7.
33. Looney WB, Archer VE. Radium inhalation accident; radium excretion study. Am J Roentgenol Radium Ther Nucl Med 1956;75:548-58.
34. Salant W, Meyer GM. The elimination of radium in normal and nephrectomized animals. Am J Physiol 1907;20:366-7.
35. Hursh JB, Lovaas A. Biliary excretion of radium in dogs. Health Phys 1960;6:183-8.
36. Hursh JB, Lovaas A, Piccirilli A, Putnam TE. Urinary excretion of radium in dogs. Am J Physiol 1960;199:513-6.
37. Sansom BF, Garner RJ. The metabolism of radium in dairy cows. Biochem J 1966;99:677-81.
38. Lloyd RD, Mays CW, Taylor GN, Atherton DR, Bruenger FW, Jones CW. Radium-224 retention, distribution, and dosimetry in beagles. Radiat Res 1982;92:280-95.
39. Kennel SJ, Lankford T, Garland M, Sundberg JP, Mirzadeh S. Biodistribution of 225Ra citrate in mice: retention of daughter radioisotopes in bone. Nucl Med Biol 2005;32:859-67. doi: 10.1016/j.nucmedbio.2005.05.009.